3/26
05:49 am
cprx
Catalyst Pharmaceuticals (CPRX) was upgraded by Truist Financial Corporation to "strong-buy".
Low
Report
Catalyst Pharmaceuticals (CPRX) was upgraded by Truist Financial Corporation to "strong-buy".
3/16
02:51 am
cprx
A Look At Catalyst Pharmaceuticals (CPRX) Valuation After Recent Share Price Softness [Yahoo! Finance]
Low
Report
A Look At Catalyst Pharmaceuticals (CPRX) Valuation After Recent Share Price Softness [Yahoo! Finance]
3/15
10:29 pm
cprx
Is Catalyst Pharmaceuticals (CPRX) Pricing Reflect Long Term Value After Rare Disease Interest? [Yahoo! Finance]
Low
Report
Is Catalyst Pharmaceuticals (CPRX) Pricing Reflect Long Term Value After Rare Disease Interest? [Yahoo! Finance]
3/14
03:29 pm
cprx
Catalyst Pharmaceuticals Touts Firdapse Growth, Agamree Traction as Fycompa Faces Generics [Yahoo! Finance]
Low
Report
Catalyst Pharmaceuticals Touts Firdapse Growth, Agamree Traction as Fycompa Faces Generics [Yahoo! Finance]
3/12
02:45 am
cprx
Full Year 2025 Trading Update [Yahoo! Finance]
Medium
Report
Full Year 2025 Trading Update [Yahoo! Finance]
3/10
05:42 pm
cprx
Catalyst Pharmaceuticals, Inc. (CPRX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
Low
Report
Catalyst Pharmaceuticals, Inc. (CPRX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
3/10
11:06 am
cprx
Catalyst Pharmaceuticals: Exceptional Fundamentals Trading at 20-33% Discount [Yahoo! Finance]
Low
Report
Catalyst Pharmaceuticals: Exceptional Fundamentals Trading at 20-33% Discount [Yahoo! Finance]
3/9
02:25 am
cprx
AGAMREE® (vamorolone) Data Presented at MDA 2026 Confirm Comparable Long-Term Effectiveness for up to 8 Years of Treatment, with Clinically Meaningful Safety Advantages in Duchenne Muscular Dystrophy [Yahoo! Finance]
Medium
Report
AGAMREE® (vamorolone) Data Presented at MDA 2026 Confirm Comparable Long-Term Effectiveness for up to 8 Years of Treatment, with Clinically Meaningful Safety Advantages in Duchenne Muscular Dystrophy [Yahoo! Finance]
3/6
08:25 am
cprx
Catalyst Pharmaceuticals to Showcase Real-World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference [Yahoo! Finance]
Low
Report
Catalyst Pharmaceuticals to Showcase Real-World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference [Yahoo! Finance]
3/6
08:03 am
cprx
Catalyst Pharmaceuticals to Showcase Real-World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference
Low
Report
Catalyst Pharmaceuticals to Showcase Real-World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference
3/6
02:22 am
cprx
Why Catalyst Pharmaceuticals (CPRX) Is Up 5.4% After Raising 2026 Revenue Guidance And Highlighting Rare Disease Portfolio [Yahoo! Finance]
Low
Report
Why Catalyst Pharmaceuticals (CPRX) Is Up 5.4% After Raising 2026 Revenue Guidance And Highlighting Rare Disease Portfolio [Yahoo! Finance]
3/5
07:56 am
cprx
Catalyst Pharmaceuticals (CPRX) was upgraded by Zacks Research from "hold" to "strong-buy".
Low
Report
Catalyst Pharmaceuticals (CPRX) was upgraded by Zacks Research from "hold" to "strong-buy".
3/3
01:06 pm
cprx
Catalyst Pharmaceuticals (CPRX) had its price target raised by Citigroup Inc. from $33.00 to $35.00. They now have a "buy" rating on the stock.
Low
Report
Catalyst Pharmaceuticals (CPRX) had its price target raised by Citigroup Inc. from $33.00 to $35.00. They now have a "buy" rating on the stock.
3/1
04:40 am
cprx
Catalyst Pharmaceuticals (CPRX) Reports Record Q4 and Full Year 2025 Results [Yahoo! Finance]
Medium
Report
Catalyst Pharmaceuticals (CPRX) Reports Record Q4 and Full Year 2025 Results [Yahoo! Finance]
2/28
08:32 pm
cprx
Is Catalyst Pharmaceuticals (CPRX) Pricing Reflect Its Strong DCF Upside After Recent Flat Returns [Yahoo! Finance]
Medium
Report
Is Catalyst Pharmaceuticals (CPRX) Pricing Reflect Its Strong DCF Upside After Recent Flat Returns [Yahoo! Finance]
2/26
07:02 pm
cprx
Catalyst Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Medium
Report
Catalyst Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
2/26
04:04 pm
cprx
Catalyst Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
Catalyst Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
2/25
04:36 pm
cprx
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance [Yahoo! Finance]
Low
Report
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance [Yahoo! Finance]
2/25
04:07 pm
cprx
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance
Medium
Report
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance
2/24
08:33 am
cprx
Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare Conference [Yahoo! Finance]
Low
Report
Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare Conference [Yahoo! Finance]
2/24
08:03 am
cprx
Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare Conference
Low
Report
Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare Conference
2/19
11:49 am
cprx
Catalyst Pharmaceuticals: Clear Path Forward For Growth In 2 FDA-Approved Drugs [Seeking Alpha]
Low
Report
Catalyst Pharmaceuticals: Clear Path Forward For Growth In 2 FDA-Approved Drugs [Seeking Alpha]
2/11
08:53 am
cprx
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026 [Yahoo! Finance]
Low
Report
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026 [Yahoo! Finance]
2/11
08:03 am
cprx
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026
Low
Report
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026
2/7
04:17 pm
cprx
Catalyst Pharmaceuticals (NASDAQ:CPRX) shareholders have earned a 41% CAGR over the last five years [Yahoo! Finance]
Medium
Report
Catalyst Pharmaceuticals (NASDAQ:CPRX) shareholders have earned a 41% CAGR over the last five years [Yahoo! Finance]